Mitotane adjuvant monotherapy (ACC)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-MITOTANE |
|---|
| ID | REG-MITOTANE-ADJUVANT-ACC |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-07-11 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ADIUVO-TERZOLO-2023 SRC-ENSAT-ACC-2018 SRC-ESMO-ACC-2020 |
Notes
STUB pending clinical co-lead sign-off (CHARTER §6.1). Dosing/ titration/monitoring figures (starting dose 2-3 g/day, up-titration ~q2wk, target level 14-20 mg/L, monitoring cadence) sourced from the EU SmPC for mitotane (Mitotane Esteve 500 mg tablets); broadly consistent with ENSAT/ESMO guideline framing but not independently cross-checked against the primary ENSAT/ESMO guideline text in this pass — verify against institutional protocol before clinical use. Target population (high recurrence risk after R0 resection) defined by RF-ACC-HIGH-RECURRENCE-RISK-BIOLOGY.
Used By
Algorithms
ALGO-ACC-1L- ALGO-ACC-1L
Indication
IND-ACC-1L-RESECTION-MITOTANE- IND-ACC-1L-RESECTION-MITOTANE
Regimen
REG-EDP-M-ACC- EDP-M (etoposide + doxorubicin + cisplatin + mitotane) — FIRM-ACT regimen